Dr Reddy’s Laboratories Ltd plans to step up sales of biosimilars, or copies of complex biotech drugs, in emerging markets in the next few years. Biosimilars are a lucrative category of medicines that is expected to generate billions of dollars in sales in the next few years, but Indian drugmakers are lagging their Western peers in launching biosimilars in developed markets. Dr Reddy’s, India’s No. 2 drugmaker by sales, generated $94 million from selling biosimilars to emerging markets between 2012 and 2015, and plans to launch products in Russia in the next few years. It is also looking at licensing opportunities in Southeast Asia
It also has plans to expand its generics business into Brazil and Colombia, and is considering acquisitions.